LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in … Read more
Market Cap & Net Worth: LB Pharmaceuticals Inc Common Stock (LBRX)
LB Pharmaceuticals Inc Common Stock (NASDAQ:LBRX) has a market capitalization of $220.51K ($220.51K) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #39208 globally and #12773 in its home market, demonstrating a 0.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LB Pharmaceuticals Inc Common Stock's stock price $24.42 by its total outstanding shares 9030 (9.03K).
LB Pharmaceuticals Inc Common Stock Market Cap History: 2025 to 2026
LB Pharmaceuticals Inc Common Stock's market capitalization history from 2025 to 2026. Data shows growth from $201.01K to $220.51K (0.00% CAGR).
LB Pharmaceuticals Inc Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LB Pharmaceuticals Inc Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LBRX by Market Capitalization
Companies near LB Pharmaceuticals Inc Common Stock in the global market cap rankings as of March 18, 2026.
Key companies related to LB Pharmaceuticals Inc Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
LB Pharmaceuticals Inc Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, LB Pharmaceuticals Inc Common Stock's market cap moved from $201.01K to $ 220.51K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $220.51K | +9.70% |
| 2025 | $201.01K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of LB Pharmaceuticals Inc Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $220.51K USD |
| MoneyControl | $220.51K USD |
| MarketWatch | $220.51K USD |
| marketcap.company | $220.51K USD |
| Reuters | $220.51K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.